Jia Liu/LinkedIn
Jul 21, 2025, 11:15
Jia Liu: Whether Dose Escalation Trials are Fit for ADC Drug Development
Jia Liu, Translational Lead, Early Phase Drug Development at The Kinghorn Cancer Centre , shared on LinkedIn:
“And Professor Jayesh Desai from Peter MacCallum Cancer Centre discussing dose escalation trials and whether they are fit for purpose for ADC drug development – need for collaboration to ensure we enrol the right patients on the right trials, toxicity assessment given narrow therapeutic index and emergence of screening multiplex IHCs needed.”
More posts featuring Jia (Jenny) Liu.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 21, 2025, 11:15
Jul 21, 2025, 10:57
Jul 21, 2025, 10:44
Jul 21, 2025, 10:24
Jul 21, 2025, 10:13
Jul 20, 2025, 20:20